STRO SUTRO BIOPHARMA, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1382101 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-34.4%
TTM net income YoY-74.9%
TTM EPS YoY-2,761.9%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-175.7%
Net margin-205.2%
FCF margin—
EBITDA margin-168.5%
Returns
ROE-1,810.0%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.32x
Leverage & solvency
Liabilities / assets141.6%
Debt / equity—
Current ratio2.53x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $102.48M | $62.04M |
| R&D expense | $166.42M | $252.04M |
| SG&A expense | $41.02M | $48.45M |
| Operating income | -$158.37M | -$238.45M |
| Pretax income | -$191.18M | -$225.10M |
| Income tax | -$93,000 | $2.36M |
| Net income | -$191.09M | -$227.46M |
| EBITDA | -$151.04M | -$231.24M |
| EPS (basic) | -22.49 | -29.40 |
| EPS (diluted) | -22.49 | -29.40 |
| Weighted avg. shares (diluted) | 8.50M | 7.74M |
| Balance sheet | ||
| Cash & equivalents | $58.13M | $190.30M |
| Short-term investments | $83.30M | $126.59M |
| Receivables | $3.98M | $8.62M |
| Current assets | $150.93M | $343.31M |
| PP&E, net | $10.65M | $18.19M |
| Total assets | $173.83M | $387.21M |
| Current liabilities | $75.13M | $131.89M |
| Total liabilities | $306.28M | $342.61M |
| Shareholders' equity | -$132.45M | $44.60M |
| Shares outstanding | 8.58M | 8.31M |
| Cash flow statement | ||
| Operating cash flow | -$177.23M | -$191.54M |
| Investing cash flow | $45.01M | $218.51M |
| Financing cash flow | $44,000 | $94.05M |
| Depreciation & amortization | $7.32M | $7.22M |
| Stock-based compensation | $14.01M | $24.69M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.